Virginia Prepares to Accept Applications for a Single Medical Cannabis License for Health Service Area 1, Which Includes the Shenandoah Valley - Foley Hoag
Virginia is opening a single medical cannabis license for Health Service Area 1 (Shenandoah Valley). This creates a limited opportunity for pharmaceutical manufacturers to enter the state's medical cannabis market, but also imposes strict regulatory requirements.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 28, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. Pharmaceutical manufacturers (branded, generic, API, contract, compounding) interested in medical cannabis production in Virginia should confirm how it applies to their specific situation before acting. There is a time constraint attached: Application window opens soon; specific deadline not yet published but expected to be short. Monitor Virginia Board of Pharmacy announcements.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
Virginia announced it will accept applications for a single medical cannabis license in Health Service Area 1, covering the Shenandoah Valley. This is a new, exclusive license opportunity with a limited window.
Who it affects
Pharmaceutical manufacturers (branded, generic, API, contract, compounding) interested in medical cannabis production in Virginia
What you must do
Prepare and submit a license application before the deadline, ensuring compliance with Virginia's medical cannabis regulations, including cGMP, DEA controlled substance requirements, and state-specific rules.
Deadline
Application window opens soon; specific deadline not yet published but expected to be short. Monitor Virginia Board of Pharmacy announcements.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- GLP‑1 Compliance: FDA Targets Telehealth Marketing in 30 New Warning Letters - JD Supra
- Court of Appeals Affirms Judgment that Struck Down Rule Mandating Price Disclosure in Pharmaceutical Ads - Holland & Knight
- Glenmark suffers recall, warning letter after subpar investigation into tablet manufacturing glitch - Fierce Pharma
- February 17, 2026: Pennsylvania compounding pharmacy earns another FDA warning letter - Partnership for Safe Medicines
- Governor signs bill requiring informed consent for nursing home patients for prescription of antipsychotic drugs - Oklahoma State Senate (.gov)